IR@PKUHSC  > 北京大学第二临床医学院  > 内分泌科
学科主题临床医学
China type 2 diabetes treatment status survey of treatment pattern of oral drugs users
Ji, Linong1; Lu, Juming2; Weng, Jianping3; Jia, Weiping4; Tian, Haoming5; Zhu, Dalong6; Xing, Xiaoping7; Guo, Lixin8
关键词oral drugs treatment type 2 diabetes
刊名JOURNAL OF DIABETES
2015-03-01
DOI10.1111/1753-0407.12165
7期:2页:166-173
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Endocrinology & Metabolism
资助者Novartis Pharma, Beijing, China ; Novartis Pharma, Beijing, China
研究领域[WOS]Endocrinology & Metabolism
关键词[WOS]POSTPRANDIAL HYPERGLYCEMIA ; ANTIDIABETIC DRUGS ; DIAREGIS REGISTRY ; HYPOGLYCEMIA ; MELLITUS ; PREVALENCE ; INHIBITOR ; METFORMIN ; AGENTS ; RISK
英文摘要

BackgroundThe aim of the present study was to investigate the current status of oral anti-diabetic drug (OAD) therapy in patients with type 2 diabetes and influencing factors in a real-world setting in China.

MethodsA total of 9872 outpatients with type 2 diabetes, who had received OADs (monotherapy or combination therapy) for at least 3 months were recruited in this study. Current antidiabetic treatment regimen and related clinical data were collected from medical records and analyzed.

ResultsThe most common OADs in use were insulin secretagogues (70.2%) such as sulfonylureas (SUs; 42.7%) or glinides (27.5%), followed by metformin (53.7%), -glucosidase inhibitors (35.9%), thiazolidinediones (17.2%), and dipeptidyl peptidase-4 (DPP-4) inhibitors (0.8%). Dual-drug combination therapy was more common (45.4%) than monotherapy (35.8%) and combination therapy with at least three drugs (17.0%). Patients on SU or glinide monotherapy were more likely to alter their treatment frequently (odds ratio [OR], 1.7; 95% CI, 1.38-2.08; P<0.001).

ConclusionsThe status of OAD use in China is varied with a majority of the patients altering their treatment regimen citing poor effectiveness. These observations from a real-world setting may serve as guidance for improving diabetes management in China.

语种英语
资助者Novartis Pharma, Beijing, China ; Novartis Pharma, Beijing, China
WOS记录号WOS:000349127200007
Citation statistics
Cited Times:10[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/63245
Collection北京大学第二临床医学院_内分泌科
作者单位1.Peking Univ, Peoples Hosp, Dept Endocrinol, Beijing 100853, Peoples R China
2.Chinese Peoples Liberat Army Gen Hosp, Dept Endocrinol, Beijing 100044, Peoples R China
3.Sun Yat Sen Univ, Affiliated Hosp 3, Dept Endocrinol, Guangzhou 510275, Guangdong, Peoples R China
4.Shanghai 6th Hosp, Dept Endocrinol, Shanghai, Peoples R China
5.West China Hosp, Dept Endocrinol, Chengdu, Peoples R China
6.Beijing Hosp, Dept Endocrinol, Beijing, Peoples R China
7.Nanjing Drum Tower Hosp, Dept Endocrinol, Nanjing, Jiangsu, Peoples R China
8.Beijing Union Med Coll Hosp, Dept Endocrinol, Beijing, Peoples R China
Recommended Citation
GB/T 7714
Ji, Linong,Lu, Juming,Weng, Jianping,et al. China type 2 diabetes treatment status survey of treatment pattern of oral drugs users[J]. JOURNAL OF DIABETES,2015,7(2):166-173.
APA Ji, Linong.,Lu, Juming.,Weng, Jianping.,Jia, Weiping.,Tian, Haoming.,...&Guo, Lixin.(2015).China type 2 diabetes treatment status survey of treatment pattern of oral drugs users.JOURNAL OF DIABETES,7(2),166-173.
MLA Ji, Linong,et al."China type 2 diabetes treatment status survey of treatment pattern of oral drugs users".JOURNAL OF DIABETES 7.2(2015):166-173.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Ji, Linong]'s Articles
[Lu, Juming]'s Articles
[Weng, Jianping]'s Articles
百度学术
百度学术Similar articles in
[Ji, Linong]'s Articles
[Lu, Juming]'s Articles
[Weng, Jianping]'s Articles
必应学术
必应学术Similar articles in
[Ji, Linong]'s Articles
[Lu, Juming]'s Articles
[Weng, Jianping]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.